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Abstract
Snakebite envenoming is a major public health burden in tropical parts of the developing
world. In sub-Saharan Africa, neglect has led to a scarcity of antivenoms threatening the
lives and limbs of snakebite victims. Technological advances within antivenom are war-
ranted, but should be evaluated not only on their possible therapeutic impact, but also on
their cost-competitiveness. Recombinant antivenoms based on oligoclonal mixtures of
human IgG antibodies produced by CHO cell cultivation may be the key to obtaining better
snakebite envenoming therapies. Based on industry data, the cost of treatment for a snake-
bite envenoming with a recombinant antivenom is estimated to be in the range USD 60–250
for the Final Drug Product. One of the effective antivenoms (SAIMR Snake Polyvalent
Antivenom from the South African Vaccine Producers) currently on the market has been
reported to have a wholesale price of USD 640 per treatment for an average snakebite.
Recombinant antivenoms may therefore in the future be a cost-competitive alternative to
existing serum-based antivenoms.
Author summary
Given the medical importance of snakebite envenoming and the current shortage of anti-
venoms in sub-Saharan Africa, technological advances in antivenom development and
production are needed. One of the avenues that could be taken involves the use of recom-
binant antivenoms based on oligoclonal mixtures of human IgG antibodies, since these
may have the benefits of being compatible with the human immune system and their pro-
duction is independent on animal immune systems and venom procurement. However,
an important aspect of introducing recombinant antivenoms to the clinic is their cost of
production given that snakebite victims are often poor rural workers living in remote parts
of the tropical parts of the developing world. Here, we aim to provide cost estimates of
recombinant antivenom manufacture with special focus on snakebite envenoming in
sub-Saharan Africa. Our results indicate that recombinant antivenoms in the future will
indeed be cost-competitive compared to existing animal-derived serum-based antivenoms.
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Furthermore, we outline different manufacturing strategies and suggest the use of caprylic
acid precipitation as a low cost purification method following cultivation of CHO cells for
antibody expression due to its use in current antivenom manufacture.
Introduction
The global disease burden from snakebite envenoming is massive, and particularly affecting
poor rural tropical areas in Africa, Asia, Oceania, and Latin America [1]. The incidence of
envenoming is estimated to be in the order of 2–3 million per year, resulting in more than
100,000 deaths [2,3]. Although animal-derived antisera remain the cornerstone of snakebite
therapy [4], biotechnological advances are driving the emergence of different antivenom for-
mats based on human or camelid antibody scaffolds [5,6], which in the future may pave the
way for recombinant oligoclonal mixtures of antivenom antibodies [7]. The potential benefits
of recombinant antivenoms for treatment of snakebite envenoming include higher potency
and fewer side effects (serum sickness and anaphylaxis is not uncommon from animal-derived
antisera) due to the possibility of producing fully human antibody formats specifically target-
ing the medically relevant snake venom toxins [6,8]. In the production of serum-based anti-
venoms, the therapeutically relevant antibodies targeting snake venom toxins cannot easily be
separated from the therapeutically irrelevant antibodies targeting other targets (e.g. bacteria or
vira that the immunized animal has encountered during its life. In contrast, recombinant anti-
venoms may be produced with a significantly higher concentration of therapeutically active
antibodies than current serum-based antivenoms, which are known to only contain between
5–36% specific antibodies directed against venom components [9–11]. However, lack of cost-
competitive production of antivenom antibody mixtures remains a critical hurdle against
making such medicines widely available in poor rural regions of the developing world.
Four families of venomous snakes exist (Elapidae, Viperidae, Atractaspididae, and Colubri-
dae), of which the elapids (such as mambas, cobras, and coral snakes) and viperids (such as
rattlesnakes and other vipers) are responsible for the vast majority of envenomings [12]. Gen-
erally, viperid venoms are cytotoxic, hemotoxic, and occasionally myotoxic, whereas elapid
venoms primarily cause systemic neurotoxicity [12]. The difference in clinical manifestations
of viper and elapid venoms stem from the different families of toxins in the snake venom. Fur-
ther, some of the venom toxins act independently of each other, whereas for others the toxicity
is potentiated via toxin synergism [13]. Neurotoxins must first pass the systemic circulation
before reaching the relevant targets in the central nervous system and are therefore typically
rather small in size. In contrast, toxins which induce tissue damage, including proteases, cyto-
toxins, and myotoxins, are larger proteins which primarily exert their destructive effects at the
site of the bite. This difference in site of action for different toxins means that antivenoms
against locally-acting toxins need to be able to reach distal sites and deep tissue [14], whereas
rapid distribution in the circulatory system may be sufficient for effective delivery of antiven-
oms against systemic toxicity.
Currently, animal-derived snakebite antivenoms are manufactured in three different struc-
tural formats: IgG-based, F(ab)2-based, and Fab-based [6,14] (see Fig 1). F(ab)2 and Fab-based
are generated with the intention of creating improved safety profiles through the removal
of the Fc region of the animal-derived IgG antibodies by treatment with pepsin or papain dur-
ing the manufacturing process [7]. Fab-based antivenoms have been shown to better reach
and neutralize toxins in deep tissue than IgG-based antivenoms, but it comes at a cost of
reduced serum half-life [14]. In comparison, F(ab)2-based antivenoms have pharmacokinetic
properties somewhat in between IgG-based antivenoms and Fab-based antivenoms [14].
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Therefore, different antivenom formats have different benefits and drawbacks. The IgG format
may represent a more optimal solution for targeting systemically acting toxins, whereas the
Fab format may potentially be more ideal against locally acting toxins. Other formats have
been investigated, including single-chain variable fragments (scFv) and camelid single-domain
antibodies (VHH fragments) [5–7], but none of these are have yet been tested in the clinic.
The standard method for purification of IgGs from the plasma of immunized animals is
based on caprylic (octanoic) acid precipitation [15]. This method is inexpensive and robust,
but also leaves unwanted traces of caprylic acid in the final product. In order to increase the
purity of antivenoms, additional chromatographic steps can be applied, although this leads to
lower production yield and significantly higher production cost [16]. Caprylic acid precipita-
tion of IgGs from plasma should be compared to recombinant mAb production, where the
standard methods of purification are based on affinity chromatography using protein A cap-
ture. The advantage of protein A chromatography is that it leads to a purer product. However,
the method is also significantly more expensive, and the resins used for affinity binding of anti-
bodies have a limited number of uses [17,18], typically 150–200 (personal communication
with Anne Tolstrup, Biogen (Denmark) A/S).
For large-scale production of monoclonal recombinant antibodies, Chinese Hamster Ovary
(CHO) cell-based expression systems are most common [19], partially due to their ability to
produce glycosylation patterns similar to human patterns. CHO cell expression is traditionally
performed in a fed-batch process (see Fig 2), where nutrients for the CHO cells are supplied
for a complete manufacturing process followed by harvest of the entire batch. The antibodies
from this batch are then purified by one or more chromatographic purification steps. Other
cost-competitive production processes, such as hybrid and continuous perfusion processes
(see Fig 2) are emerging [20]. In the hybrid process, cultivation is performed in a fed-batch
reactor followed by continuous or semi-continuous purification of the produced antibodies.
In the continuous perfusion process, the cultivated cells are retained while the growth medium
containing the antibodies is continuously substituted with fresh medium in a perfusion reac-
tor. The used medium undergoes a continuous or semi-continuous purification process in
Fig 1. Overview of the three antibody formats commonly used in serum-based antivenoms. IgG is the entire native immunoglobulin G, whereas the
formats F(ab)2 and Fab are obtained by enzymatic cleavage in the hinge region with pepsin or papain, respectively.
doi:10.1371/journal.pntd.0005361.g001
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order to isolate the antibodies [20,21] (see Fig 2). In the continuous perfusion process, several
companies in the industry are employing continuous chromatographic procedures, such as
Simulated Moving Bed Chromatography (SMBC) (personal communication with Mads Laust-
sen, Symphogen A/S). This procedure allows for efficient use of chromatographic media as
well as it yields higher output of purified product [22]. In the work presented here, we base our
calculations on hybrid and continuous perfusion processes using SMBC as downstream pro-
cess [21]. In addition, we compare the results of these calculations with a manufacturing setup,
where the hybrid and continuous processes employ caprylic acid precipitation as purification
method [20], since this downstream process poses as a cost-competitive alternative that is
already employed in existing antivenom manufacture.
In later years, a growing interest in producing mixtures of monoclonal antibodies has emerged
based on an expectation that improved antibody-based therapies can be obtained by targeting more
than one target in multiple different indications. Two different strategies can be employed to pro-
duce such antibody mixtures: 1) Mixing of individually produced parallel batches of each monoclo-
nal antibody (Fig 3A) [23–25] and 2) oligoclonal expression of antibodies in a single batch (Fig 3B),
exemplified by Merus’ Oligoclonics technology [26] and Symphogen’s Sympress technology [23,25].
In the Oligoclonics technology, a single cell line is transfected with a shared light chain and 2–3 dif-
ferent heavy chains giving rise to several different specificities. In the Sympress technology, a range
of clonal cell lines each expressing different antibodies are mixed together in a single batch in order
Fig 2. Overview of the three different antibody manufacturing process strategies: In the fed-batch process, nutrients for the CHO cells are
supplied for a complete cultivation process followed by harvest and purification of the entire batch by single-batch chromatography. In the
continuous perfusion process, cells are retained while the growth medium containing the antibodies is continuously substituted with fresh medium in a
perfusion reactor. The used media undergoes simulated moving bed chromatography (SMBC), where the chromatographic processes are conducted in a
continuous process as described in [22]. In the hybrid process, cultivation is performed in a fed-batch reactor followed by SMBC instead of single-batch
chromatography.
doi:10.1371/journal.pntd.0005361.g002
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to produce a mix of a desired number of specific antibodies. The Oligoclonics technology limits the
number of different specificities as the single cell line expression system gives rise to stability chal-
lenges with higher numbers of different heavy chains [27]. The Sympress technology on the other
hand allows for any number of different specificities as each antibody specificity is produced by a
separate cell line [23,25].
A single monoclonal antibody is unlikely to be able to effectively neutralize a snake venom,
given the complexity of snake venoms, which each contain numerous different toxins from
different protein families [8]. Instead, mixtures of antibodies will be needed in order to neu-
tralize most of the medically relevant snake venom toxins [6–8,28]. Moreover, it is desirable to
have polyvalent antivenoms that target the venom toxins from more than just a single snake
species, since it is not always possible for clinicians to identify the perpetrating snake species
with certainty. Therefore, a clear need exists for technologies enabling cost-competitive pro-
duction of oligoclonal antibody mixtures, if recombinant antivenoms are to be introduced.
Actual proof of concept studies on the production of recombinant antivenoms have never
been reported. However, sufficient knowledge from related areas within antibody expression
and CHO cell cultivation exists to assess the utility and cost-competitiveness of future recom-
binant antivenoms. Here, we provide an estimate of the production costs of oligoclonal recom-
binant antivenoms based on industry data and discuss the implications that novel antibody
expression technologies may have on future snakebite envenoming therapy. Antivenoms are
likely to be produced with the aim of being able to neutralize most of the medically relevant
snakebites in a particular region of the world, but not the entire world. Therefore, we base our
present estimates on a hypothetical polyvalent antivenom that could be used to treat the
approximately one million snakebite envenomings occurring each year in sub-Saharan Africa,
as such pan-African antivenoms derived from animal serum already exist for comparison.
Fig 3. Schematic representation of two different strategies for recombinant expression of antibody
mixtures. A) Mixing of batches: Antibodies are produced by monoclonal expression in different bioreactors,
followed by individual purification, after which they are mixed to yield the final oligoclonal antivenom product.
B) Oligoclonal expression: Antibodies are produced by oligoclonal expression in one bioreactor containing
different cell lines. Purification can then be performed on the mix of antibodies, providing the final oligoclonal
antivenom.
doi:10.1371/journal.pntd.0005361.g003
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Methods
Estimation of the minimum need for therapeutically active antibodies in
antivenom in sub-Saharan Africa
The estimate of the minimum need for active antibodies (active pharmaceutical ingredient, API)
to neutralize snakebite envenoming is critical for establishing the maximum cost of production
for a recombinant antivenom, as this cost is highly dependent on the scale of production. Here,
the minimum need for active antibodies is based on the number of snakebite envenomings in
sub-Saharan Africa (approximately one million victims) [2], the average number of vials needed
to treat an envenoming (for the representative SAIMR Snake Polyvalent Antivenom from the
South African Vaccine Producers), which is estimated to be between 6 and 10 vials per treatment
[29], the volume and protein content of this antivenom (10 mL and 172 mg/mL) (as measured by
their absorbance at 280 nm on a NanoDrop 2000c instrument, Thermo Scientific) [30], and the
lowest estimate (5%) of the percentage of venom-recognizing antibodies in an antivenom (rang-
ing between 5% and 36%) [9–11]. In fact, the amount of therapeutically active antibodies is likely
to be even lower, since not all venom components are medically relevant, yet still induce an
immune response during the animal immunization process. Also, we assume that antibodies pro-
duced recombinantly are equipotent (mol-to-mol) to the therapeutically active antibodies found
in current antivenoms, and we take the difference in molecular weight between IgG molecules
and F(ab)2 fragments into account in the calculation of the minimum need of antibodies. Finally,
we do not take into account any amount of antivenom that may be discarded due to expiration.
Cost of Goods Manufactured (COGM) per gram for oligoclonal antibody
production
The cost of recombinant monoclonal antibodies is highly dependent on the manufacturing
approach and the scale of production. The Cost of Goods Manufactured of Active Pharmaceuti-
cal Ingredient (COGMAPI) has been analyzed extensively on several occasions [20,31,32]. Pro-
duction costs of monoclonal antibodies range from 36 USD/g to 1500 USD/g depending on the
manufacturing facilities used [20,33] and when the process was developed (personal communi-
cation with Anne Tolstrup, Biogen (Denmark) A/S). We base our calculations on the Sympress
technology, as this has been successfully employed in the development and production of several
oligoclonal antibody-based therapies that have entered clinical trials (http://www.symphogen.
com/pipeline). The COGMAPI of recombinant oligoclonal antibodies is estimated to be 0–10%
higher than the production cost of conventional mAbs [25]. In our analysis, four manufacturing
situations (annual production of 100 kgAPI, 200 kgAPI, 500 kgAPI, and 1,000 kgAPI), based on
reported cost estimates for fed-batch, hybrid, and continuous perfusion processes [31] were
employed to estimate COGMAPI for oligoclonal antibody production. The reported cost esti-
mates in [31] are calculated based on SMBC as the purification process, using the most realistic
assumptions for fed-batch, hybrid, and continuous perfusion, where the fed-batch reactors are
used multiple times to obtain titers of 3 g/L, and where continuous perfusion is performed with
a cell specific perfusion rate (CSPR) of 0.05 nL per cell-1 d-1 with a titer of 0.4 g/L [21].
Cost of Goods Manufactured (COGM) per treatment for oligoclonal
recombinant antivenoms
To estimate the COGMAPI for a snakebite treatment using oligoclonal recombinant antiven-
oms at a scale of 500 kgAPI, direct costs of 62 USD/g (fed-batch), 47 USD/g (hybrid), and 89
USD/g (continuous perfusion) (determined in the previous section) were employed (also see
Fig 4). Estimates were based on two different relative amounts (5% and 20%) of therapeutically
Production of recombinant antivenoms
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active antibodies present in current antivenoms. The number of vials per average treatment
for the SAIMR Snake Polyvalent Antivenom from the South African Vaccine Producers was
based on data published in [29]. Vial volume and protein concentration are equal to those
given above. Finally, to estimate the Cost of Goods Manufactured for the final drug product
(COGMFDP) the cost of formulation and packaging was (in discussion with Mads Laustsen,
Symphogen A/S) estimated to be 5 USD/vial, which is five times the cost reported for current
antivenoms in [34], and the upper limit for the concentration of active antibodies in 10 mL
vials with recombinant oligoclonal antivenom was set to 100 mg/mL. For comparison, we per-
formed cost estimates based on an alternative set of numbers for production of oligoclonal
recombinant antivenom using caprylic acid precipitation as the purification method for hybrid
and continuous perfusion processes at a scale of 500 kgAPI. Here, we applied COGMAPI from
[20] for commercial production and added 10% for oligoclonal production [25]: 46 USD/g for
fed-batch cultivation followed by single-batch chromatography, 33 USD/g for hybrid (fed-
batch cultivation followed by continuous precipitation-based purification), and 42 USD/g for
continuous perfusion followed by continuous precipitation-based purification.
Results and discussion
Minimum antivenom need in sub-Saharan Africa
The unit cost of recombinant antibody production is highly dependent on the scale of antibod-
ies produced [31,35]. To estimate the order of magnitude of the amount of antibodies needed
to treat all snakebites in sub-Saharan Africa, we disregarded the fact that many antivenoms
may not be used for effective therapeutic treatment of victims due to expiration or loss during
the supply chain. Thus, we made the assumption that manufacturing volume equals need,
which may not be the case in reality. Also, we only considered the therapeutically active anti-
bodies in current antivenoms, which are likely to be no more than the amount of antibodies in
antivenoms that are able to recognize snake toxins: 5% to 36% [9–11], since there is no reason
to include ineffective antibodies, when producing antibodies using a recombinant approach.
In our assessment of the sub-Saharan African need, we employed the lowest average number
of vials (6 vials, 10 mL/vial) reported for the SAIMR Snake Polyvalent Antivenom from the
South African Vaccine Producers [29] and the lowest estimate of the content of therapeutically
active antibodies in this antivenom, being 5%. Based on these assumptions, we provide the
conservative estimate that the sub-Saharan African need for therapeutically active antivenom
antibodies to be at least 500 kgAPI per year. This number does not represent a precise estima-
tion of the actual need, however, it provides a lower estimate of the magnitude required for
production of antibodies for recombinant antivenoms, which may further be used to estimate
the COGMAPI (USD/gram) for the manufacture of recombinant antibodies. In reality, the real
need may be in the order of 1 to 2 tonAPI per year (if e.g. the assumed content of therapeutically
active antibodies is assumed to be 10–20% instead of only 5% for the SAIMR Snake Polyvalent
Antivenom from the South African Vaccine Producers). However, increasing the production
volumes above 250 kgAPI per year has limited influence on COGMAPI [31] (disregarding any
possible capital investment needed in reality to modify production facilities), see Fig 4.
Cost of Goods Manufactured (COGM) for oligoclonal recombinant
antivenoms
In our assessment of the COGMAPI for oligoclonal recombinant antivenoms produced via a
fed-batch, hybrid, and continuous perfusion process, we employed cost estimates provided by
industry [31] according to a scale of production in the range of 500 kgAPI per year is estimated
Production of recombinant antivenoms
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in the section above (see Fig 4 for cost as a function of scale of production). At this scale, the
COGMAPI for production of oligoclonal antibody mixtures is estimated to 62 USD/g for a fed-
batch process, 47 USD/g for a hybrid process, and 89 USD/g for a continuous perfusion pro-
cess in agreement with similar cost estimates reported in literature [20,25,31,36,37].
To compare the COGMAPI per treatment, we here employed both a low estimate (5% of the
antivenom antibodies are active) and an estimate that we consider more realistic (20% of the
antivenom antibodies are active) based on numbers from [9–11]. In these calculations, we
assumed that the average snakebite envenoming requires 8 vials (10 mL/vial) of SAIMR Snake
Polyvalent Antivenom [29]. As it can be seen in Fig 5A, the COGMAPI per treatment for oligo-
clonal recombinant antivenoms at a scale of 500 kgAPI estimated to be between USD 58–233 in
fed-batch mode, USD 44–176 in hybrid mode, and USD 83–334 in continuous perfusion
mode based on the low and high estimates of the content of therapeutically active antibodies
in an antivenom.
In order to estimate the Cost of Goods Manufactured for the Final Drug Product
(COGMFDP), which includes formulation and packaging, we used a cost estimate of 5 USD/
vial. We further assumed that each 10 mL vial could be formulated with an antibody concen-
tration of up to 100 mg/mL, but that for administration purposes an average envenoming
should be treated with at least 4 vials. This would allow a physician to easily administer less
antivenom for milder envenomings requiring a dose lower than average. Since much fewer
antibodies are needed in a recombinant antivenom compared to traditional antisera, as only
the therapeutically active antibodies are manufactured, these criteria had the effect that treat-
ments with all antibody formats would meet the minimum requirement of 4 vials for
Fig 4. Estimation of Cost of Goods Manufactured (COGM) per gram for oligoclonal antibody production at different scales of production for
three different manufacturing strategies, Fed-batch, hybrid, and continuous perfusion (all using chromatography as purification method,
see Fig 2), based on cost estimates from [25,31].
doi:10.1371/journal.pntd.0005361.g004
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formulation, adding 20 USD to the COGM of treatment. The COGMFDP per treatment is
therefore estimated to USD 78–253 in fed-batch mode, USD 64–196 in hybrid mode, and USD
103–354 in continuous perfusion mode (see Fig 5A). The fairly broad estimates for each indi-
vidual situation derives from the uncertainty of how many therapeutically active antibodies
actually exist in the existing SAIMR Snake Polyvalent Antivenom. In these estimates, we
employed a percentage between 5% and 20%, which corresponds to a 4-fold increase from the
lowest estimate to the highest. More knowledge and better understanding of the therapeutic
content of existing antivenoms would be useful to narrow down the cost estimates presented
here. Even more desirable, however, would be to have proof of concept recombinant antiven-
oms with a defined set of discovered and tested human monoclonal antibodies upon which
better cost estimates could be performed. As effective doses of individual antibodies in real
case scenarios may span 1–2 log units, having such a defined set of antibodies with specific
ED50s would allow for bottom-up calculations based on optimal molecular ratios between
antibodies (removing the need for assuming equipotency (mol-to-mol) of antiserum-based
antibodies and recombinantly produced antibodies, see Methods). In real case scenarios, mini-
mum requirements for antibody efficacy and ease of expression should be imposed as selection
criteria to ensure that the antibodies selected for a recombinant antivenom are compatible
with oligoclonal expression methods (e.g. Sympress or Oligoclonics).
Since caprylic acid precipitation is routinely employed in the manufacture of current anti-
venoms [15], a comparison of the COGMFDP per treatment for oligoclonal recombinant anti-
venoms produced using continuous caprylic acid precipitation for the hybrid and continuous
perfusion processes was performed. Based on numbers from [20,25], the COGMAPI was in this
case estimated to 46 USD/g for fed-batch cultivation followed by single-batch chromatogra-
phy, 33 USD/g for hybrid (fed-batch cultivation followed by continuous precipitation-based
purification), and 42 USD/g for continuous perfusion followed by continuous precipitation-
based purification. These cost estimates based on the application of caprylic acid precipitation
for the hybrid and continuous process are significantly lower than the estimates based on
Fig 5. Estimation of Cost of Goods Manufactured (COGM) per snakebite treatment for oligoclonal antibody production at a production scale of
500 kgAPI for three different manufacturing strategies: Fed-batch, hybrid, and continuous perfusion. A) Cost estimated based numbers from [31],
employing SMBC as purification method for the hybrid and continuous perfusion processes. B) Cost estimated based numbers from [20], employing
continuous caprylic acid precipitation as purification method for the hybrid and continuous perfusion processes instead of continuous SMBC. API: Active
Pharmaceutical Ingredient. FDP: Final Drug Product.
doi:10.1371/journal.pntd.0005361.g005
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processes employing chromatography. Using these lower cost estimates therefore leads to a
significant lowering of the COGMAPI, estimated to USD 43–173 for fed-batch mode, USD 31–
124 for hybrid mode, and USD 39–158 for continuous perfusion mode. When including 4
vials for formulation, the COGMFDP is estimated to USD 63–193 for fed-batch mode, USD
51–144 for hybrid mode, and USD 59–178 for continuous perfusion mode (see Fig 5B). Our
results may therefore point towards the applicability of caprylic acid precipitation for manu-
facture of recombinant antivenoms due to its lower cost and compliance with current anti-
venom manufacture. In general, since we estimate the cost estimates on oligoclonal expression
by adding 10% to the COGMAPI for oligoclonal antibodies compared to monoclonal antibod-
ies, the cost estimates presented here subtracted these 10% may also be valid for the production
of recombinant antivenoms based on monoclonal antibodies against animal venoms, where
venom toxicity can be abrogated by targeting a single toxin (or more toxins with a cross-reac-
tive antibody).
The COGM estimates (approx. USD 60–350 per treatment for processes using chromatog-
raphy as purification method and approx. USD 50–190 per treatment for processes using
caprylic acid precipitation as purification method) presented here compare favorably with
the wholesale cost of SAIMR Snake Polyvalent Antivenom (USD 640 per treatment) [29].
Although the wholesale cost may not adequately reflect the COGMFDP for SAIMR Snake Poly-
valent Antivenom, our COGMFDP estimates for recombinant production indicate that even
with a fairly high margin for distribution, sales, and profit (45–92% depending on manufactur-
ing strategy and purification method), that snakebite envenoming treatments based on recom-
binant antivenoms could be cost-competitive with current serum-based antivenoms.
In this feasibility study, we focus on the production of IgG-based antibodies, since other
antibody formats, such as Fab, scFv, or VHH would not be produced in CHO cells, but rather
in prokaryotic systems (personal communication with Mads Laustsen, Symphogen A/S). We
therefore do not intend to provide an in-depth discussion on any therapeutic or pharmacoki-
netic benefits that some antibody formats may have above others. Some of these differences
include the bivalency of IgG and F(ab)2 and the prolonged half-life of IgG compared to both F
(ab)2, Fab, scFv, and VHH fragments [6,14,38,39]. The shorter half-life of F(ab)2s, Fabs, scFvs,
and VHHs makes it likely that larger doses of these more rapidly degraded formats are needed
to effectively neutralize all venom toxins in a snakebite envenoming. Also, even for systemi-
cally acting neurotoxins that are able to reach their targets within minutes, a delayed release of
toxins from the bite site may occur over a period of days, demanding either repeated doses or
longer serum half-life of the antivenom [40]. On the other hand, smaller fragments may possi-
bly penetrate faster into distal tissue, where venom toxins are initially located following a
snakebite, possibly providing therapeutic benefits to the use of smaller fragments. It is likely
that Fabs, scFv, or VHH-based recombinant antivenoms could be produced in large scale at an
even lower cost using prokaryotic systems that do not require expensive media, and which
have a high growth rate and productivity. A COGM analysis comparing the different formats
and taking the molecular and pharmacokinetic differences into account is, however, beyond
the scope of this study as we deem it to be too speculative, given the large amount of assump-
tions that would need to be made. Since the majority of current antivenoms (including the
SAIMR Snake Polyvalent Antivenom) are based on the F(ab)2 format [6], which has a compa-
rable molecular size and bivalence, the COGM estimates presented here may indeed provide a
rough assessment of the relative cost-competitiveness of IgG-based antivenoms. Moreover, the
human IgG format with its long half-life has never been thoroughly explored in the field of
antivenom, and it may indeed provide additional benefits such as lower administration doses
needed for the treatment of a snakebite envenoming. The data presented here therefore war-
rant further research into the development of recombinant antivenoms. Additionally, a need
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presents itself for discussing how to handle regulatory affairs, when a switch from conventional
antisera (which are defined as “blood products”) to recombinant antivenoms (probably to be
defined as “biopharmaceuticals/biologics”) occurs.
As a final remark, the cost of recombinant antibody production has been hypothesized to
possibly reach as low levels as 10–20 USD/g in the longer term [33,36,41]. Although reaching
such a low cost of production may be years into the future and require a larger scale than what
is relevant for antivenoms, it may indicate that the cost of recombinant antivenoms in the
future may be even lower than what is estimated here.
Conclusions
Based on industrial cost estimates of oligoclonal expression of antibodies at large scale and the
estimated need for therapeutically active antibodies to treat the one million snakebite enve-
nomings occurring each year in sub-Saharan Africa, we estimate that recombinant pan-Afri-
can antivenoms could be produced with a COGMAPI of 62 USD/g (fed-batch), 47 USD/g
(hybrid process), and 89 USD/g (continuous perfusion), when chromatography is used as
purification method, and 46 USD/g (fed-batch), 33 USD/g (hybrid process), and 42 USD/g
(continuous perfusion), when caprylic acid precipitation is used as purification method for
the hybrid and continuous perfusion process. This translates into an approximate Cost of
Goods Manufactured for the IgG-based final drug product including vials and formulation
(COGMFDP) between approx. USD 60–350 per treatment (for processes using chromatogra-
phy as purification method) and approx. USD 50–190 per treatment (for processes using
caprylic acid precipitation as purification method) for treating an average snakebite envenom-
ing that would normally require 8 vials of SAIMR Snake Polyvalent Antivenom from the
South African Vaccine Producers [29]. These estimates compare favorably with previously
reported costs of treatment ranging from USD 56 to 640 for current serum-based antivenoms
[29], leaving a large margin (45–92%) for formulation, distribution, sales, and profit when
comparing with the golden standard antivenom, SAIMR Snake Polyvalent Antivenom.
The data-supported cost estimates presented here may provide better insight into the eco-
nomics of recombinant antivenom production and help guide decision processes on what
technological platforms future antivenoms should be built on. Our estimates demonstrate the
cost-competitiveness of the production of recombinant antivenoms, which may provide incen-
tive to more researchers to engage in the development and testing of such novel therapies
against snakebite envenoming.
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